Skip to main content
    T

    Taysha Gene Therapies Inc (TSHA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.06
    -0.04 (-0.98%)

    Market Cap: $1.34B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Taysha Gene Therapies Inc (TSHA) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Taysha Gene Therapies are Tyra Biosciences (TYRA), Structure Therapeutics Inc. American Depositary Shares (GPCR) and 4D Molecular Therapeutics (FDMT). By market cap, Taysha Gene Therapies ranks 8th of the 13 companies on this page; Beam Therapeutics (BEAM) is the largest at $2.36B.

    Peer Comparison

    TSHA's ROIC of -32.8% is above the peer median of -38.1%, and its revenue growth of 171.3% is above the median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Taysha Gene Therapies (TSHA)$1.34BN/A300.6x0.0%-32.8%171.3%0.00%
    Tyra Biosciences Inc (TYRA)$1.38BN/AN/A0.0%N/A0.0%0.00%
    Structure Therapeutics Inc. American Depositary Shares (GPCR)$1.43BN/AN/A0.0%N/A0.0%0.00%
    4D Molecular Therapeutics Inc (FDMT)$689.52MN/A8.5x-208.6%-46.4%4506.0%0.00%
    Beam Therapeutics Inc (BEAM)$2.36BN/A15.0x-73.9%-29.7%-96.8%0.00%
    Theravance Biopharma Inc (TBPH)$884.18M95.1x8.4x51.6%N/A-20.9%0.00%
    Alpha Tau Medical Ltd (DRTS)$1.24BN/AN/A0.0%-176.9%0.0%0.00%
    Rapport Therapeutics, Inc. Common Stock (RAPP)$1.55BN/A59.3x0.0%N/A0.0%0.00%
    Sarepta Therapeutics Inc (SRPT)$1.72BN/A0.8x-5.9%-3.2%-4.5%0.00%
    Design Therapeutics Inc (DSGN)$670.46MN/AN/A0.0%N/A0.0%0.00%
    Precigen Inc (PGEN)$1.63B98.6x9.9x15.5%18.9%2438.0%0.00%
    Silence Therapeutics PLC (SLN)$1.23BN/A882.5x0.0%N/A197.2%0.00%
    Vera Therapeutics Inc (VERA)$2.03BN/A189.3x0.0%-83.0%0.0%0.00%
    Peer median$1.41B96.9x12.4x0.0%-38.1%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Taysha Gene Therapies, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Tyra Biosciences Inc (TYRA)
    Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and improve outcomes...
    TYRA competitors
    Structure Therapeutics Inc. American Depositary Shares (GPCR)
    Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic...
    GPCR competitors
    4D Molecular Therapeutics Inc (FDMT)
    4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops candidate products using its adeno-associated virus vectors.
    FDMT competitors
    Beam Therapeutics Inc (BEAM)
    Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States.
    BEAM competitors
    Theravance Biopharma Inc (TBPH)
    Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe...
    Alpha Tau Medical Ltd (DRTS)
    Alpha Tau Medical Ltd., a clinical-stage oncology therapies company, is engaged in the research, development...
    DRTS competitors
    Rapport Therapeutics, Inc. Common Stock (RAPP)
    Rapport Therapeutics, Inc. is a pioneering biotechnology company dedicated to the advancement of therapeutics for neurodegenerative diseases...
    RAPP competitors
    Sarepta Therapeutics Inc (SRPT)
    Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy...
    SRPT competitors
    Design Therapeutics Inc (DSGN)
    Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions.
    DSGN competitors
    Precigen Inc (PGEN)
    Precigen, Inc. discovers and develops the next generation of cell and gene therapies in the United States. The company is headquartered in Germantown, Maryland.
    PGEN competitors
    Silence Therapeutics PLC (SLN)
    Silence Therapeutics plc, a biotechnology company, is focused on the discovery and development of new ribonucleic acid (RNA) therapies in hematology...
    SLN competitors
    Vera Therapeutics Inc (VERA)
    Vera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immune diseases...
    VERA competitors

    Frequently Asked Questions About TSHA

    Who are Taysha Gene Therapies' main competitors?

    The companies most similar to Taysha Gene Therapies include Tyra Biosciences (TYRA), Structure Therapeutics Inc. American Depositary Shares (GPCR), 4D Molecular Therapeutics (FDMT), Beam Therapeutics (BEAM) and Theravance Biopharma (TBPH), listed from the closest match.

    Who is Taysha Gene Therapies' biggest competitor?

    Beam Therapeutics (BEAM) is the largest of the similar companies at $2.36B; Tyra Biosciences (TYRA) is the closest match by business profile, size, sector and industry.

    How does TSHA stock compare with its competitors?

    TSHA's P/S is 300.6x against a peer median of 12.4x; its net margin is 0.0% against a peer median of 0.0%.

    Which of Taysha Gene Therapies' competitors pays a higher dividend?

    Taysha Gene Therapies pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Taysha Gene Therapies bigger than its competitors?

    No. Taysha Gene Therapies is 8th by market cap among the 13 companies on this page; the largest is Beam Therapeutics (BEAM) at $2.36B.